Preliminary application of .sup.125I-nivolumab to detect PD-1 expression in colon cancer via SPECT

The precise detection of PD-1/PD-L1 biomarkers helps to predict the prognosis of corresponding immunotherapy. .sup.125I-labeled nivolumab targeting activated immune cells infiltrating the tumorous tissues was developed to evaluate the expression of PD-1 immune checkpoints. SPECT images indicated tha...

Full description

Saved in:
Bibliographic Details
Published in:Journal of radioanalytical and nuclear chemistry 2018-11, Vol.318 (2), p.1237
Main Authors: Li, Danni, Wang, Cheng, Zhang, Dakuan, Peng, Ye, Ren, Shengnan, Li, Xiao, Zuo, Changjing
Format: Article
Language:English
Subjects:
B cells
Cancer screening
Colon cancer
Immunotherapy
Medical imaging equipment
Medical schools
Single photon emission computed tomography
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The precise detection of PD-1/PD-L1 biomarkers helps to predict the prognosis of corresponding immunotherapy. .sup.125I-labeled nivolumab targeting activated immune cells infiltrating the tumorous tissues was developed to evaluate the expression of PD-1 immune checkpoints. SPECT images indicated that .sup.125I-nivolumab preferentially targeted to tumor-surrounded immune cells. This radiotracer can dynamically and quantitatively characterize the in vivo expression of immune checkpoints for colorectal cancer, thereby potentially enabling the early screening of patients, monitoring the efficacy of treatment, and assessing potential immunotoxicity.
ISSN:0236-5731
DOI:10.1007/s10967-018-6124-6